Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for ImageneBio, Inc. (IMA).
- 2 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 16 Apr 2026, 19:23.
ORBIMED ADVISORS LLC - 14 Apr 2026 Form 4 Insider Report for ImageneBio, Inc. (IMA)
- Reporting relationship
- Director
- Issuer ticker
- IMA
- Reported as of
- 14 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Apr 2026, 19:23:53 UTC
- Prior SEC filing
- 09 Apr 2026
- Next SEC filing
- 28 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for ImageneBio, Inc. (IMA) on 16 Apr 2026.
Change
- Previous filing in this sequence was filed on 09 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (3)
CIK 0001055951
Primary reporting owner
ORBIMED ADVISORS LLC
- Relationship
- Director
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- Signature date
- 16 Apr 2026
CIK 0001682115
OrbiMed Capital GP VI LLC
- Relationship
- Director
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP VI LLC
- Signature date
- 16 Apr 2026
CIK 0001808744
OrbiMed Genesis GP LLC
- Relationship
- Director
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC
- Signature date
- 16 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 753,062
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Footnotes
- F3, F5
IMA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 753,062
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Footnotes
- F3, F5
IMA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 753,062
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Footnotes
- F3, F5
IMA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,691
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Footnotes
- F4, F5
IMA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,691
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Footnotes
- F4, F5
IMA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,691
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Footnotes
- F4, F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMA
transaction
Derivative
Pre-Funded Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +336,603
- Change %
- Price
- Shares after
- 336,603
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 336,603
- Exercise price
- $0.001000
- Footnotes
- F1, F2, F3, F5
IMA
transaction
Derivative
Pre-Funded Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +336,603
- Change %
- Price
- Shares after
- 336,603
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 336,603
- Exercise price
- $0.001000
- Footnotes
- F1, F2, F3, F5
IMA
transaction
Derivative
Pre-Funded Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +336,603
- Change %
- Price
- Shares after
- 336,603
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 336,603
- Exercise price
- $0.001000
- Footnotes
- F1, F2, F3, F5
IMA
transaction
Derivative
Pre-Funded Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +384,689
- Change %
- Price
- Shares after
- 384,689
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 384,689
- Exercise price
- $0.001000
- Footnotes
- F1, F2, F4, F5
IMA
transaction
Derivative
Pre-Funded Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +384,689
- Change %
- Price
- Shares after
- 384,689
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 384,689
- Exercise price
- $0.001000
- Footnotes
- F1, F2, F4, F5
IMA
transaction
Derivative
Pre-Funded Warrants (right to buy)
Purchase
- Transaction value
- Shares
- +384,689
- Change %
- Price
- Shares after
- 384,689
- Date
- 14 Apr 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 384,689
- Exercise price
- $0.001000
- Footnotes
- F1, F2, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
On April 12, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional and accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 14, 2026 (the "Closing Date") pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 721,292 Shares. The price per Pre-Funded Warrant is $5.199.
Footnote F2
The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 19.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.
Footnote F3
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
Footnote F4
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
Footnote F5
This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Bonita is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.